These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 7746278)

  • 21. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
    Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID
    Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
    Utsugi T; Mattern MR; Mirabelli CK; Hanna N
    Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH
    Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
    Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
    Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK
    Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
    Webb CD; Latham MD; Lock RB; Sullivan DM
    Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
    Bojanowski K; Lelievre S; Markovits J; Couprie J; Jacquemin-Sablon A; Larsen AK
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3025-9. PubMed ID: 1313577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S; Austin CA; Fisher LM
    Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
    Barret JM; Calsou P; Larsen AK; Salles B
    Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
    J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
    Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
    Sullivan DM; Latham MD; Ross WE
    Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
    Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.